

Nasal Polyps

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

Trial Status
Completed

Trial Runs In
10 Countries

Trial Identifier
NCT03280550 2017-001724-22
GA39688

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to determine the efficacy and safety of omalizumab compared with placebo in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP) who have had an inadequate response to standard-of-care treatments. Study GA39855 (POLYP 2; NCT03280537) was another Phase III study by the Sponsor with identical objectives and design and was run in parallel with this study.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03280550 2017-001724-22 GA39688
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 75 Years

Healthy Volunteers
No
